Invention Grant
- Patent Title: Fibroblast growth factor-21-Fc fusion proteins
-
Application No.: US17410307Application Date: 2021-08-24
-
Publication No.: US11944664B2Publication Date: 2024-04-02
- Inventor: Brian R. Boettcher , Shari Lynn Caplan , Douglas S. Daniels , Norio Hamamatsu , Stuart Licht , Stephen Craig Weldon
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Morgan, Lewis & Bockius LLP
- The original application number of the division: US14630206 2015.02.24
- Main IPC: C07K14/50
- IPC: C07K14/50 ; A61K38/18 ; A61K45/06 ; A61K38/00
Abstract:
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Public/Granted literature
- US20210386824A1 Nucleic Acids Encoding FGF21-Fc Fusion Proteins Public/Granted day:2021-12-16
Information query
